|
    ABEO U.S.: Nasdaq

    Abeona Therapeutics Inc.

    ABEOUS
    After Hours
    Last Updated: Sep 17, 2021 6:57 p.m. EDT Delayed quote

    $ 1.2200

    0.02 1.67%
    After Hours Volume: 98.89K
    Close Chg Chg %
    $1.2000 -0.0400 -3.23%
    Advanced Charting
    Volume: 865.66K 65 Day Avg: 1.06M
    82% vs Avg
    1.1700 Day Range 1.2700
    0.9895 52 Week Range 3.7899

    Your Watchlists

    Customize eLesor

    Have Watchlists? Log in to see them here or sign up to get started.

    Symbol
    Company
    Price
    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    ABEO Overview

    Performance

    5 Day
    • -6.98%
    1 Month
    • 2.56%
    3 Month
    • -29.41%
    YTD
    • -23.57%
    1 Year
    • -42.31%

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 3 Full Ratings

    Recent News

    Abeona Therapeutics Named Edward Carr CFO

    Abeona Therapeutics Completes Type B Meeting With FDA

    Abeona Therapeutics Sees Positive Data in Trial for Sanfilippo Syndrome Treatment

    Abeona Therapeutics started at buy with $5 stock price target at B. Riley FBR

    Abeona Therapeutics started at outperform with $6 stock price target at SVB Leerink

    Abeona Therapeutics stock price target cut to $14 from $26 at Maxim Group

    Read full story

    In Health Care, Fidelity Targets Secular Growth

    UPDATE: Abeona shares rise 10% on 'regenerative medicine advanced therapy' designation from FDA

    Abeona shares rise 6% on 'regenerative medicine advanced therapy' designation from FDA

    Read full story

    The Russell 2000 is diverging from the S&P 500 — should you worry?

    Abeona Therapeutics started at buy with $26 stock price target at SunTrust RH

    Read full story

    Harry Boxer’s three biotech-stock breakouts to watch

    Read full story

    These signals show the punch is coming out of the stock market

    Read full story

    Harry Boxer’s four stocks to watch today

    Read full story

    These factors signal the stock market is a buy

    Read full story

    S&P 500 buy signals hold their ground amid Tuesday’s selloff

    Read full story

    S&P 500 is on the verge of a breakout to the upside

    Read full story

    Harry Boxer’s four biotech stocks to watch

    Abeona Therapeutics stock price target raised to $14 from $8 at Maxim Group

    Read full story

    Abeona Expands Opportunity With Partnerships

    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

    on InvestorPlace.com

    H.C. Wainwright Thinks Abeona Therapeutics’ Stock is Going to Recover

    on TipRanks.com

    Abeona Therapeutics (ABEO) Receives a Buy from H.C. Wainwright

    on SmarterAnalyst

    Abeona Therapeutics (ABEO) Receives a Buy from Leerink Partners

    on SmarterAnalyst

    Moving Average Crossover Alert: Abeona Therapeutics (ABEO)

    on Zacks.com

    7 Penny Stocks That May Not Be Penny Stocks For Long

    on InvestorPlace.com

    H.C. Wainwright Sticks to Its Buy Rating for Abeona Therapeutics (ABEO)

    on SmarterAnalyst

    Abeona Therapeutics (ABEO) Receives a Buy from Leerink Partners

    on SmarterAnalyst

    Abeona Therapeutics (ABEO) Reports Q4 Loss, Lags Revenue Estimates

    on Zacks.com

    Billionaire Ken Griffin Pulls the Trigger on These 2 Penny Stocks

    on TipRanks.com

    H.C. Wainwright Remains a Buy on Abeona Therapeutics (ABEO)

    on SmarterAnalyst

    Abeona Therapeutics (ABEO) Gets a Buy Rating from H.C. Wainwright

    on SmarterAnalyst

    Do Options Traders Know Something About Abeona (ABEO) Stock We Don't?

    on Zacks.com

    Verastem (VSTM) Begins Phase II Combo Study for Ovarian Cancer

    on Zacks.com

    Is the Options Market Predicting a Spike in Abeona (ABEO) Stock?

    on Zacks.com

    Biogen (BIIB) & Sage Therapeutics Partner for Depression Therapies

    on Zacks.com

    HorizonTherapeutics (HZNP) Rises YTD on Approvals & Buyouts

    on Zacks.com

    Eiger (EIGR) Gets FDA Approval for Zokinvyin Rare Diseases

    on Zacks.com

    Horizon (HZNP) and Halozyme Ink Deal for ENHANZE Technology

    on Zacks.com

    Amgen (AMGN) Ends Deal With Cytokinetics for Heart Candidate

    on Zacks.com

    Abeona Therapeutics Inc.

    Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.

    Competitors

    Name Chg % Market Cap
    Johnson & Johnson -0.28% $433.7B
    Madrigal Pharmaceuticals Inc. 1.98% $1.36B
    Ironwood Pharmaceuticals Inc. Cl A 2.24% $2.01B
    Enzon Pharmaceuticals Inc. 2.40% $27.36M
    BioDelivery Sciences International Inc. -2.44% $393.4M
    Competitor Data Provided ByCapital Cube Logo